Driving Drug Device Combination Market Growth in 2025: The Role of Rising Prevalence Of Chronic Diseases Fuels Growth In Drug-Device Combination Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Drug Device Combination Market Size Growth Forecast: What to Expect by 2025?
The market size for drug device combinations has seen a swift expansion in the recent past. The market, which is forecasted to escalate from $131.01 billion in 2024 to $144.22 billion in 2025, is expected to see a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the previous period is due to the surge in medical innovation, increase in chronic illnesses, adoption of patient-focused approaches, progress in biologics, issues with monotherapy, and evolving clinical needs.

How Will the Drug Device Combination Market Size Evolve and Grow by 2029?
Expectations are that the drug device combination market will experience significant expansion in the coming years, with its size forecasted to reach $224.68 billion in 2029, reflecting a compound annual growth rate (CAGR) of 11.7%. This predicted growth in the forecast period can be linked to factors such as increased patient participation and involvement, digital transformation in healthcare, the expansion of the global market, the introduction of innovative treatment approaches, and value-based healthcare. Key trends projected for the forecast period encompass advancements in therapy, management of complex diseases, a focus on patient-centered care, technological innovations, and supportive regulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/drug-device-combination-global-market-report

What Drivers Are Propelling the Growth of Drug Device Combination Market Forward?
The escalating occurrence of chronic illnesses is predicted to propel the drug-device combination market. A chronic disease is a long-lasting condition that lasts a year or more, disrupts daily life, requires ongoing medical attention, or both. Heart disease and diabetes are examples of such chronic conditions. Drug-device combinations are diagnostic and therapeutic products designed to provide efficient treatment for individuals with chronic diseases. For example, a study by the World Health Organization, the United Nations' specialised agency dedicated to global public health, reported that more than 420 million people worldwide had diabetes in 2022. These figures are projected to rise to 578 million and 700 million by 2030 and 2045, respectively. Therefore, the rising occurrence of chronic diseases is fuelling the expansion of the drug-device combination market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8206&type=smp

What Are the Key Trends Driving Drug Device Combination Market Growth?
In a bid to solidify their dominance in the drug combination device market, leading corporations are focusing on product innovation such as the development of Trelegy Ellipta. This tool is an inhaler that enables efficient dosing of medication into the lungs. It's groundbreaking in the sense that it's the first single-inhaler triple therapy. GSK, a biotechnology and pharmaceutical firm out of the UK, rolled out Trelegy Ellipta to the market in April 2022. These inhalers are highly portable due to their compact nature. Their use primarily lies in managing chronic obstructive pulmonary disease (COPD) and asthma. Ellipta inhalers are capable of housing three varied types of medications in their foil packaging for combination therapy. Integrated into its design is the combination of three medicinal components: fluticasone furoate, umeclidinium, and vilanterol, making Trelegy Ellipta a peculiar drug combination device. This aids in enhancing the patient's management of respiratory conditions via a system that delivers medication in a manner that's well-integrated.

What Are the Key Segments in the Drug Device Combination Market?
The drug device combination market covered in this report is segmented -

1) By Product: Auto-Injector, Microneedle Patch, Digital Pill, Smart Inhaler, Drug Delivery Hydrogels, Drug-Eluting Lens, Other Products
2) By Distribution Channel: Direct Tender, Retails Sales, Other Distribution Channels
3) By Application: Orthopedic Diseases, Respiratory Diseases, Diabetes, Oncology, Cardiovascular Diseases, Other Applications
4) By End User: Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers, Other End Users

Subsegments:
1) By Auto-Injector: Pre-Filled Auto-Injectors, Reusable Auto-Injectors
2) By Microneedle Patch: Dissolving Microneedle Patches, Coated Microneedle Patches
3) By Digital Pill: Ingestible Sensors, Smart Capsules
4) By Smart Inhaler: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
5) By Drug Delivery Hydrogels: Injectable Hydrogels, Topical Hydrogels
6) By Drug-Eluting Lens: Contact Lenses, Intraocular Lenses
7) By Other Products: Transdermal Patches, Implantable Drug Delivery Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8206&type=smp

Who Are the Key Players Shaping the Drug Device Combination Market's Competitive Landscape?
Major companies operating in the drug device combination market are The 3M Company, Abbott India Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic PLC, Ypsomed Holding AG, Micron Biomedical Inc., MetP Pharma AG, Sonceboz SA, Lepu Medical Technology (Beijing) Co. Ltd., Eitan Medical Ltd., Vaxess Technologies Inc., Subcuject Aps, Allergan PLC, Terumo Corporation, Stryker Corporation, Becton dic*kinson and Company, Zimmer Biomet Holdings Inc., MediPrint Ophthalmics, Arrow International Inc., Alcon Inc., W. L. Gore & Associates Inc., Cook Medical LLC, Pinnacle Biologics Inc.

What Geographic Markets Are Powering Growth in the Drug Device Combination Market?
North America was the largest region in the drug-device combination market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug device combination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8206

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.